Madrigal Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Madrigal Pharmaceuticals Inc (MDGL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Madrigal Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,428M vs 398,321M combined for its competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+20.8% annualized vs trailing 12 months), vs accelerating (+8.2%) for its tracked peer group.
- Growth: Madrigal Pharmaceuticals Inc generated 50.1% revenue growth year over year in Q3 2026, vs 14.6% for its competitors combined.
- Profitability: Its 12.9% net margin compares with 17.6% for the peer group.
- Scale: Madrigal Pharmaceuticals Inc ranks #34 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.2% of industry market cap.
- Peer revenue share: Madrigal Pharmaceuticals Inc accounted for 0.4% of combined revenue among its tracked peer group, up from 0.3% a year earlier.
- Peer differentiation: Revenue per employee of $1.56M compares with $0.99M for the peer group (1.6x).
- Structure: Madrigal Pharmaceuticals Inc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MDGL Sales vs. its Competitors, Q3 2026
Madrigal Pharmaceuticals Inc reported revenue growth of 50.13 % year on year in Q3 2026, above its competitors' combined revenue growth of 14.64 %.
With a net margin of 12.86 %, Madrigal Pharmaceuticals Inc reported lower profitability than its competitors (17.58 %).
Madrigal Pharmaceuticals Inc generated 0.40 % of the combined sales of its peer group, up from 0.30 % a year earlier.
API endpoints for this dataset
Madrigal Pharmaceuticals Inc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Madrigal Pharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Madrigal Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Madrigal Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Madrigal Pharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 50.1% for Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals Inc's share of combined industry revenue moved from 0.06% to 0.08%, a gain of 0.02 percentage points.
Madrigal Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | No | Yes | Yes | Yes |
| Competitors combined (144) | ||||
| High-Confidence Competitors (2) | - | |||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDGL Stock Performance relative to its Competitors
MDGL Stock Performance relative to High-Confidence Competitors
MDGL Stock Performance relative to Similar-Size Competitors
MDGL Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inmed Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 4 | Erasca Inc | 282.9% | Outperformed |
| 5 | Climb Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Madrigal Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Madrigal Pharmaceuticals Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Madrigal Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Madrigal Pharmaceuticals Inc |
13,119.22 | 1,427.94 |
 Eli Lilly And Company |
1,261,319.90 | 86,462.00 |
 Johnson and Johnson |
690,774.55 | 99,335.00 |
 Abbvie Inc |
519,727.60 | 66,014.00 |
 Merck and Co Inc |
367,313.70 | 66,569.00 |
 Novartis Ag |
320,013.95 | 56,674.00 |
| SUBTOTAL | 4,612,683.55 | 721,388.60 |
Sign in to see all competitors of Madrigal Pharmaceuticals Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Madrigal Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Madrigal Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Madrigal Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Sagimet Biosciences inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Genfit S a | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Intercept Pharmaceuticals inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Madrigal Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Madrigal Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
Madrigal Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | 13,119 | 1,560,590 | -169,905 |
| Eli Lilly And Company | 1,261,320 | 1,729,240 | 551,594 |
| Johnson and Johnson | 690,775 | 705,504 | 114,311 |
| Abbvie Inc | 519,728 | 1,158,140 | 181,509 |
| Merck and Co Inc | 367,314 | 887,587 | 42,267 |
| Novartis Ag | 320,014 | 752,973 | 185,566 |
| PEERS TOTAL | 4,599,564 | 994,132 | 146,437 |
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
Madrigal Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
Madrigal Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Madrigal Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Madrigal Pharmaceuticals Inc ranks #34 of 495 companies by market capitalization in its industry, holding 0.21 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 888, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 21.10 % |
| 2 | Johnson and Johnson | 688,377 | 11.51 % |
| 3 | Beone Medicines Ltd | 628,233 | 10.51 % |
| 4 | Abbvie Inc | 519,434 | 8.69 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 34 | Madrigal Pharmaceuticals Inc | 12,614 | 0.21 % |
Market cap and industry share for the rest of Madrigal Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Madrigal Pharmaceuticals Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 29 | Alterity Therapeutics Limited | 15,545 | -31.18 % |
| 30 | Bridgebio Pharma Inc | 15,258 | 17.71 % |
| 31 | Summit Therapeutics Inc | 13,859 | -10.57 % |
| 32 | Elanco Animal Health Incorporated | 13,578 | 23.33 % |
| 33 | Hutchmed china Limited | 1,234 | 12.3% |
| 34 | Madrigal Pharmaceuticals Inc | 12,614 | -15.75 % |
| 35 | Dr Reddy s Laboratories Limited | 1,234 | 12.3% |
| 36 | Biomarin Pharmaceutical Inc | 1,234 | 12.3% |
| 37 | Tg Therapeutics Inc | 1,234 | 12.3% |
| 38 | Praxis Precision Medicines Inc | 1,234 | 12.3% |
| 39 | Protagonist Therapeutics inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Madrigal Pharmaceuticals Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Madrigal Pharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (445 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 24.78 % | 37.84 % (avg) | -13.1 pp |
| Operating Margin | -10.69 % | industry median | -17.0 pp |
| EBITDA Margin | -10.20 % | -6.50 % (avg) | -3.7 pp |
| Capital Intensity (Capex / Revenue) | 0.82 % | 7.56 % (avg) | -6.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Madrigal Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.5x | - |
| P/B | 27.9x | 4.3x | +23.6x |
| Return on Equity | -27.07 % | industry aggregate | -52.26 % |
| Return on Invested Capital | -10.18 % | -9.84 % (avg) | -0.34 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Madrigal Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | -31.31 % |
| Return on Invested Capital | -5.01 % | -10.65 % | -32.84 % | -50.35 % | -114.88 % | -85.58 % | -28.65 % | -19.35 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Madrigal Pharmaceuticals Inc's Strategic Group Map
Madrigal Pharmaceuticals Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Madrigal Pharmaceuticals Inc's trailing-12-month revenue growth of 92.8% and operating margin of -10.7% compares with an average of 81.6% growth and -11.2% margin across its 8 closest peers by combined growth, margin and ROIC -- Madrigal Pharmaceuticals Inc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Madrigal Pharmaceuticals Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Madrigal Pharmaceuticals Inc falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Madrigal Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 888 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.82 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Madrigal Pharmaceuticals Inc's dedicated Suppliers and Customers pages, not here.
Madrigal Pharmaceuticals Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Madrigal Pharmaceuticals Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Madrigal Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+20.8% annualized vs trailing 12 months).
Weaknesses
- Operating margin 17.0 points below the industry median.
- Return on equity 52.3 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.01x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (51.10 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Madrigal Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Madrigal Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +10.3 % | +9.5 % |
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Madrigal Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
Madrigal Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Madrigal Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Madrigal Pharmaceuticals Inc | - | 9.19 |
| Eli Lilly And Company | 45.84 | 14.59 |
| Johnson and Johnson | 42.68 | 6.95 |
| Abbvie Inc | 50.48 | 7.87 |
| Merck and Co Inc | 119.93 | 5.52 |
| Novartis Ag | 22.88 | 5.65 |
| PEERS AVERAGE | 43.56 | 6.39 |
Sign in to see all peers for Madrigal Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.